CA2660283C - 2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans - Google Patents

2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans Download PDF

Info

Publication number
CA2660283C
CA2660283C CA2660283A CA2660283A CA2660283C CA 2660283 C CA2660283 C CA 2660283C CA 2660283 A CA2660283 A CA 2660283A CA 2660283 A CA2660283 A CA 2660283A CA 2660283 C CA2660283 C CA 2660283C
Authority
CA
Canada
Prior art keywords
dosage form
dose
pharmaceutically acceptable
thrombocytopenia
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
CA2660283A
Other languages
English (en)
French (fr)
Other versions
CA2660283A1 (en
Inventor
Robert E. Desjardins
Rudolph Lucek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AkaRx Inc
Original Assignee
AkaRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AkaRx Inc filed Critical AkaRx Inc
Publication of CA2660283A1 publication Critical patent/CA2660283A1/en
Application granted granted Critical
Publication of CA2660283C publication Critical patent/CA2660283C/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2660283A 2006-08-08 2007-08-08 2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans Active 2029-08-08 CA2660283C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83633406P 2006-08-08 2006-08-08
US60/836,334 2006-08-08
PCT/US2007/017860 WO2008021283A2 (en) 2006-08-08 2007-08-08 Compositions and methods for increasing blood platelet levels in humans

Publications (2)

Publication Number Publication Date
CA2660283A1 CA2660283A1 (en) 2008-02-21
CA2660283C true CA2660283C (en) 2014-11-18

Family

ID=39082656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2660283A Active 2029-08-08 CA2660283C (en) 2006-08-08 2007-08-08 2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans

Country Status (8)

Country Link
US (2) US20080039475A1 (enExample)
EP (2) EP2056826B1 (enExample)
JP (3) JP2010500361A (enExample)
AU (2) AU2007284644B2 (enExample)
CA (1) CA2660283C (enExample)
ES (2) ES2452032T3 (enExample)
IL (4) IL196897A (enExample)
WO (1) WO2008021283A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1466912E (pt) * 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
WO2011019990A1 (en) * 2009-08-14 2011-02-17 Eisai, Inc. Use of e5501 for stimulating platelet production
CN112022825B (zh) * 2020-08-24 2024-03-22 瑞阳制药股份有限公司 马来酸阿伐曲泊帕片剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0620403B1 (de) * 1993-04-08 1996-12-04 ABB Management AG Misch- und Flammenstabilisierungseinrichtung in einer Brennkammer mit Vormischverbrennung
DE69629341T2 (de) * 1995-03-09 2004-06-09 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazolderivate
KR19990008109A (ko) * 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CN1966520B (zh) * 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
DE69626624T2 (de) * 1995-10-17 2003-11-27 Daiichi Suntory Pharma Co., Ltd. Medikamente gegen trhombocytopenie
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU762245B2 (en) * 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP1133291B1 (en) * 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
PT1466912E (pt) * 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
JP4324791B2 (ja) * 2003-07-17 2009-09-02 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
KR100776961B1 (ko) * 2003-08-12 2007-11-28 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 아고니스트 작용을 가지는 화합물
WO2007054783A2 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia

Also Published As

Publication number Publication date
JP6258264B2 (ja) 2018-01-10
IL245911A0 (en) 2016-07-31
EP2056826A4 (en) 2009-09-09
EP2452674B1 (en) 2014-03-26
IL196897A0 (en) 2011-08-01
IL240323A0 (en) 2015-09-24
EP2452674A3 (en) 2012-05-30
ES2470333T3 (es) 2014-06-23
JP2013047257A (ja) 2013-03-07
IL240323A (en) 2016-05-31
EP2056826B1 (en) 2014-01-08
HK1170673A1 (en) 2013-03-08
EP2056826A2 (en) 2009-05-13
WO2008021283A2 (en) 2008-02-21
JP2015221806A (ja) 2015-12-10
WO2008021283A3 (en) 2008-12-11
US20110224226A1 (en) 2011-09-15
AU2007284644A1 (en) 2008-02-21
US20080039475A1 (en) 2008-02-14
AU2007284644B2 (en) 2011-09-01
IL196897A (en) 2015-08-31
JP2010500361A (ja) 2010-01-07
ES2452032T3 (es) 2014-03-31
EP2452674A2 (en) 2012-05-16
IL240322A0 (en) 2015-09-24
AU2011253775B2 (en) 2014-02-13
CA2660283A1 (en) 2008-02-21
AU2011253775A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
US11998529B2 (en) Non-sedating dexmedetomidine treatment regimens
EP2678320B1 (en) Flumazenil complexes, compositions comprising same and uses thereof
US11478456B2 (en) Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
JP2010270110A (ja) ネオテームを含有する経口製剤
EP3733167A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
AU2011253775B2 (en) Compositions and Methods for Increasing Blood Platelet Levels in Humans
CA2818565A1 (en) Pediatric formulation
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans
EP3095466B1 (en) Pharmaceutical formulations with improved solubility and stability
JP5226732B2 (ja) 催眠用圧縮成型製剤
HK40031570A (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
IL227742A (en) Plumzanil complexes, compounds containing them and their uses

Legal Events

Date Code Title Description
EEER Examination request
FZDC Discontinued application reinstated
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260729